Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2018;378(2):113–25.

Article  CAS  PubMed  Google Scholar 

Huo G, Song Y, Liu W, Cao X, Chen P. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States. Front Pharmacol. 2024;28(15):1300183.

Article  Google Scholar 

Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R, et al. Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer. Cancer Med. 2024;13(16):e70083.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Cost-effectiveness analysis of osimertinib in advanced EGFR-mutant NSCLC. Lung Cancer. 2020;145:89–96.

Google Scholar 

Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–21.

Article  CAS  PubMed  Google Scholar 

Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016.

Book  Google Scholar 

Muston D. Informing structural assumptions for three state oncology cost-effectiveness models through model efficiency and fit. Appl Health Econ Health Policy. 2024;22(5):619–28. https://doi.org/10.1007/s40258-024-00884-2.

Article  PubMed  Google Scholar 

Chaudhary MA, Chu H, Cappelleri JC. Evaluating uncertainties in health economic models: a review and guide. Appl Stochastic Models Bus Ind. 2025;41(5):e70044.

Article  Google Scholar 

Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health. 2012;15(6):835–42.

Article  PubMed  Google Scholar 

Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55.

Article  PubMed  Google Scholar 

Westra N, Kruithof PD, Croes S, van Geel RM, Hendriks LE, Touw DJ, et al. Systematic evaluation of osimertinib population pharmacokinetic models in a cohort of Dutch adults with non-small cell lung cancer. Eur J Drug Metab Pharmacokinet. 2024;49(4):517–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu B, Gu X, Zhang Q, Xie F, Shi Y. Cost-effectiveness of osimertinib in treating EGFR-mutated non-small cell lung cancer: a modeling study in China. BMJ Open. 2018;8(5):e020603.

Google Scholar 

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development: Part 2---introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2012;1(3):1–14.

Article  Google Scholar 

Centanni M, Krishnan SM, Friberg LE. Model-based dose individualization of sunitinib in gastrointestinal stromal tumors. Clin Cancer Res. 2020;26(18):4590–8.

Article  CAS  PubMed  Google Scholar 

Svensson S, Karlsson MO, Friberg LE. Pharmacometric models for improved dose individualization of tyrosine kinase inhibitors. Clin Pharmacokinet. 2021;60(7):881–93.

Google Scholar 

Pink J, Lane S, Hughes DA. Mechanism-based approach to the economic evaluation of pharmaceuticals. Pharmacoeconomics. 2012;30(5):413–29.

Article  PubMed  Google Scholar 

ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices overview. Value Health. 2012;15(6):796–803.

Google Scholar 

Freitag A, Sarri G, Ta A, Gurskyte L, Cherepanov D, Hernandez LG. A systematic review of modeling approaches to evaluate treatments for relapsed refractory multiple myeloma: critical review and considerations for future health economic models. Pharmacoeconomics. 2024;42(9):955–1002.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [Internet]. 2022 [cited 2025 Jun 30]. Available from: https://www.nice.org.uk

Centanni M, Nijhuis J, Karlsson MO, Friberg LE. Comparative analysis of traditional and pharmacometric-based pharmacoeconomic modeling in the cost-utility evaluation of sunitinib therapy. Pharmacoeconomics. 2025;43(1):31–43.

Article  PubMed  Google Scholar 

Hill-McManus D, Marshall S, Liu J, Willke RJ, Hughes DA. Linked pharmacometric--pharmacoeconomic modeling and simulation in clinical drug development. Clin Pharmacol Ther. 2021;110(1):49–63.

Article  PubMed  Google Scholar 

Strong M, Oakley JE. When is a model good enough? Deriving the expected value of model improvement via specifying internal model discrepancies. SIAM/ASA J Uncertain Quantif. 2014;2(1):106–25.

Article  Google Scholar 

Liang F, Zhang Y, Xue Q, Yao N. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach. Front Pharmacol. 2024;4(15):1363259.

Article  Google Scholar 

Ruiz-Garcia A, Baverel P, Bottino D, Dolton M, Feng Y, González-García I, et al. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. J Pharmacokinet Pharmacodyn. 2023;50(3):147–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Q, Hoyle M, Jeet V, Gu Y, Sinha K, Parkinson B. Unravelling the association between uncertainties in model-based economic analysis and funding recommendations of medicines in Australia. Pharmacoeconomics. 2025;43(3):283–96.

Article  PubMed  Google Scholar 

Beauchemin C, Brewer J, Ahmed I, Fung M. Economic evaluation of targeted therapies in non-small cell lung cancer: a systematic review. J Oncol Pharm Pract. 2016;22(6):412–23.

Google Scholar 

Ara R, Brazier JE. Using health state utility values in models: an update on methodological issues. Curr Opin Support Palliat Care. 2017;11(1):15–21.

Google Scholar 

Lang Y, Yang J, Cao W. Immune checkpoint blockers plus chemotherapy as the first-line treatment for advanced or metastatic squamous non-small-cell lung carcinoma: a network meta-analysis and economic evaluation. Front Pharmacol. 2025;21(16):1669965.

Article  Google Scholar 

Holleman MS, Al MJ, Zaim R, Groen HJ, Uyl-de Groot CA, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020;21(1):153–64.

Article  PubMed  Google Scholar 

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(12):1718–35.

Google Scholar 

Parkin D, Briggs A, Abangma G, Lloyd A, Devlin N. Uncertainty around health state values used in cost-effectiveness analysis: how it arises and how to deal with it. Med Decis Making. 2026;46(2):130–43.

Article  PubMed  Google Scholar 

Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17–20.

Article  CAS  PubMed  Google Scholar 

Burnham KP, Anderson DR, editors. Model selection and multimodel inference: a practical information-theoretic approach. New York, NY: Springer New York; 2002

Massey FJ Jr. The Kolmogorov-Smirnov test for goodness of fit. J Am Stat Assoc. 1951;46(253):68–78.

Article  Google Scholar 

Zhu C, Han G, Wu B. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system. BMC Health Serv Res. 2023;23(1):1083.

Article  PubMed  PubMed Central  Google Scholar 

Wouterse B, van Baal P, Versteegh M, Brouwer W. The value of health in a cost-effectiveness analysis: theory versus practice. Pharmacoeconomics. 2023;41(6):607–17.

Article  PubMed  PubMed Central  Google Scholar 

Wells JC, Mullin MM, Ho C, Melosky B, Laskin J, Wang Y, et al. Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial. Lung Cancer. 2024;1(190):107529.

Article  Google Scholar 

Viray H, Piper-Vallillo AJ, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice. Cancers. 2024;16(6):1079.

Article